Overview

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood from patients with cancer, hepatitis C, or Crohn disease in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer and other diseases. PURPOSE: This laboratory study is looking at the effect of biological therapy on biomarkers in patients with untreated hepatitis C, metastatic melanoma, or Crohn disease.
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Infliximab
Interferon-alpha
Interferons
Ribavirin
Tremelimumab